April 29, 2014 Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta™ for Relapsing-Remitting Multiple Sclerosis
April 23, 2014 Synthetic Biologics' Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic
April 14, 2014 Synthetic Biologics Appoints Mark Pimentel, M.D., Chairman of New Irritable Bowel Syndrome Clinical Advisory Board
March 10, 2014 Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta™, for Multiple Sclerosis
February 26, 2014 Synthetic Biologics' Board of Directors Accepts Resignation of Long-Standing Founder and Board Member
February 13, 2014 Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity
February 10, 2014 Synthetic Biologics Announces Rhonda Voskuhl, M.D., to Present Trimesta™ Phase II Multiple Sclerosis Clinical Trial Results at the 2014 AAN Annual Meeting
